hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06322927 id: CFTsp231 id: 24_CPCR_38 type: OTHER domain: ChristieNHS briefTitle: PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma acronym: iPREFER overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2024-06-30 date: 2024-09-30 date: 2024-03-21 date: 2024-03-21 name: The Christie NHS Foundation Trust class: OTHER name: CellCentric Ltd. briefSummary: This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to them when making treatment decisions. conditions: Multiple Myeloma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 15 type: ESTIMATED name: Patient Interview measure: Patient Experience and Preference measure: Treatment and Preference Differences sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Christie NHS Foundation Trust city: Manchester state: Greater Manchester zip: M20 4BX country: United Kingdom lat: 53.48095 lon: -2.23743 hasResults: False
nctId: NCT06322914 id: 029 briefTitle: A Novel Scoring System for Predicting the Success of PCI in Patients With CTO overallStatus: COMPLETED date: 2012-01 date: 2023-11 date: 2023-11 date: 2024-03-21 date: 2024-03-21 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The investigators conducted a retrospective, single-center observational registry upon which one novel scoring system was formed and evaluated for their accuracy in predicting technical success. The investigators reviewed the clinical and angiographic records of 432 patients with 459 CTO lesions who underwent percutaneous recanalization attempts recruited between January 2012 and November 2023. The investigators aims to develop and validate a novel scoring system for predicting CTO-PCI success. conditions: Chronic Total Occlusion (CTO) studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 493 type: ACTUAL measure: PCI technical success sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: First Affiliated Hospital of Nanjing Medical University city: Nanjing state: Jiangsu zip: 210029 country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06322901 id: TDH-2018-7883 briefTitle: The Effect Of Vertical Releasing Incision On Implant Procedures acronym: Vertikal overallStatus: COMPLETED date: 2018-08-05 date: 2020-10-02 date: 2020-10-02 date: 2024-03-21 date: 2024-03-21 name: TC Erciyes University class: OTHER briefSummary: This study evaluated the clinical and biochemical aspects of flap design in dental implant applications regarding implantation success and patient comfort. In this split-mouth randomized controlled clinical trial, a vertical releasing incision was made at the distal end of the crestal incision on the test side, and the control side received a crestal incision alone. Sixty-eight implants were placed in 17 patients. Peri-implant groove fluid was collected on postsurgical days 3, 7, 30, and 90; OPG and RANKL levels were assessed to determine bone formation and resorption around the implants. Cortisol levels were assessed in peri-implant groove fluid at postsurgical days 3, 7, and 14. Visual analog scale (VAS), and swelling measurements were taken postoperatively. Panoramic and periapical X-rays were obtained immediately post-surgery and at 3 months. No significant marginal bone loss difference was observed between the test and control sides at 3 months. The RANKL/OPG ratio, cortisol levels, VAS scores, and swelling scores were higher in the test vs. control sides. Overall, while the use of a vertical incision has advantages, such as increasing the visual field of the surgeon and improving the ease of the operation, this approach should be used only when necessary, given the disadvantages of increased bone resorption mediators in the peri-implant tissue and reduced postoperative patient comfort. conditions: Bone Loss conditions: Flap Design studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 17 type: ACTUAL name: Flap measure: Bone loss measure: OPG/RANKL measure: visual analog scale (VAS) measure: cortisol levels sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erciyes University Faculty of Dentistry city: Melikgazi state: Kayseri zip: 38039 country: Turkey hasResults: False
nctId: NCT06322888 id: 23-676 briefTitle: Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D) overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-09-30 date: 2025-12-31 date: 2024-03-21 date: 2024-03-21 name: Dana-Farber Cancer Institute class: OTHER name: Breast Cancer Research Foundation briefSummary: The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer in women with dense breast tissue by studying changes that occur in breast tissue and blood as a result of participating in an exercise program.
* Waitlist Control Group conditions: Breast Cancer conditions: Breast Cancer Female studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 46 type: ESTIMATED name: Exercise Training Program measure: Change in Irisin in Exercise Group measure: Change in Irisin in Control Group measure: Change in Tissue Markers in Exercise Group measure: Change in Tissue Markers in Control Group measure: Change in Biomarkers in Exercise Group - Meso scale measure: Change in Biomarkers in Exercise Group - Mass cytometry measure: Change in Biomarkers in Control Group - Meso Scale measure: Change in Biomarkers in Control Group - Mass cytometry measure: Change in Participant Weight in Exercise Group measure: Change in Participant Weight in Control Group measure: Change in Cardiorespiratory Fitness in Exercise Group measure: Change in Cardiorespiratory Fitness in Control Group measure: 10-Repetition Max Test in Exercise Group measure: 10-Repetition Max Test in Control Group measure: Change in Minutes of Total Exercise for Exercise Group measure: Change in Minutes of Total Exercise for Control Group sex: FEMALE minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT facility: Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02115 country: United States name: Tari King, MD role: CONTACT phone: 617-632-3891 email: tking7@bwh.harvard.edu name: Tari King, MD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Dana Farber Cancer Institute city: Boston state: Massachusetts zip: 02215 country: United States name: Jennifer Ligibel, MD role: CONTACT phone: 617-632-3800 email: Jennifer_Ligibel@dfci.harvard.edu name: Jennifer Ligibel, MD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06322875 id: SKCCOL002 briefTitle: A Clinical Study to Evaluate the Efficacy and Satisfaction of RHC Serum Combined With RHC(III) Injection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-07 date: 2024-12 date: 2024-03-21 date: 2024-03-21 name: DeYi Aesthetic Medical Clinic class: OTHER briefSummary: To evaluate the efficacy and safety of recombinant humanized collagen (type III) solution for injection combined with SkinCeuticals recombinant humanized collagen (RHC) serum Participants will be assessed by subjective questionnaire (FACE-Q Satisfaction with skin,Global Aesthetic Improvement Scale, et al) and some medical instruments (VISIA,Ultrascan UC22 et al) conditions: Facial Wrinkles studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Recombinant type III humanized collagen solution for injection name: SkinCeuticals recombinant humanized collagen (RHC) serum name: Regular face cream smear measure: FACE-Q Satisfaction with skin measure: Investigator Global Aesthetic Improvement Scale (I-GAIS) Rates measure: Subject Global Aesthetic Improvement Scale (S-GAIS) Rates measure: Improvement rate assessed by Atlas measure: Change in Cutometer® dual Analysis Score measure: Change in VISIA® Skin Analysis Score measure: FACE-Q Satisfaction with Outcome measure: FACE-Q Satisfaction with skin measure: Change of the thickness and density of subjects' facial dermis measure: Changes from baseline in skin uniformity and spot area ratio measurements collected by VISIA's face image acquisition instrument. sex: FEMALE minimumAge: 30 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06322862 id: H-23042430 briefTitle: Intraoperative Intestinal Perfusion Assessment by Fluorescence Angiography in Emergency Surgery overallStatus: RECRUITING date: 2024-03-05 date: 2026-12-01 date: 2027-02-01 date: 2024-03-21 date: 2024-03-21 name: Rigshospitalet, Denmark class: OTHER briefSummary: This is a prospective, multicentre, non-randomized cohort study using real-time intraoperative visualization of bowel perfusion by indocyanine green (ICG) in all-cause bowel ischemia.
At intraoperative finding of bowel ischemia, the initial intraoperative plan is noted and resection margins marked with a steril pen. A fluorescence angiography will be performed and the surgeon will note whether the suspected ischemic bowel is perfused, whether there is a change in the resection margins in centimeters, and if the intraoperative plan has changed. If resection is indicated and the strategy of choice is an anastomosis, a renewed fluorescence angiography will be performed to assess anastomotic perfusion. conditions: Bowel; Ischemic, Acute studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Indocyanine green measure: Change of strategy measure: Anastomosis measure: Quantification using q-ICG measure: Stomas measure: Second-look measure: Anastomotic leaks measure: Postoperative medical complications measure: Postoperative surgical complications measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Organ Surgery and Transplantation status: RECRUITING city: Copenhagen state: Hovedstaden zip: 2100 country: Denmark name: Sermed Ellebæk Nicolae, MD role: CONTACT phone: +4535459666 email: sermed.ellebaek.nicolae@regionh.dk name: Michael P Achiam, MD, DMSc role: CONTACT phone: +45 3545 0441 email: michael.patrick.achiam.01@regionh.dk lat: 55.67594 lon: 12.56553 facility: Department of Surgery, Bispebjerg Hospital status: NOT_YET_RECRUITING city: Bispebjerg country: Denmark name: Peter Bonde, MD role: CONTACT lat: 55.71017 lon: 12.53147 facility: Department of Surgery, Herlev Hospital status: NOT_YET_RECRUITING city: Herlev country: Denmark name: Jakob Burcharth, MD, PhD role: CONTACT lat: 55.72366 lon: 12.43998 facility: Department of Surgery, Nordsjællands Hospital status: NOT_YET_RECRUITING city: Hillerød country: Denmark name: Mai-Britt Tolstrup, MD, PhD role: CONTACT lat: 55.92791 lon: 12.30081 facility: Department of Surgery, Hvidovre Hospital status: NOT_YET_RECRUITING city: Hvidovre country: Denmark name: Morten Laksafoss Lauritsen, MD role: CONTACT lat: 55.65719 lon: 12.47364 hasResults: False
nctId: NCT06322849 id: STU00220591 briefTitle: Active Elements of Digital Single-session Interventions overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-06 date: 2024-03-21 date: 2024-04-11 name: Northwestern University class: OTHER briefSummary: Depression is a leading cause of disability in young adults. However, access to care is limited due to structural and psychological barriers. Single-session interventions (SSIs) are structured programs designed to maximize the therapeutic output in one interaction between the patient and the provider or a program. Project ABC, a single-session intervention (SSI), has been shown to be effective in reducing depressive symptoms. Project ABC is based on four components-psychoeducation, testimonials, saying is believing exercises, and action planning. However, it is unclear what are the effects of the individual components.
Additionally, the exploratory aim of this study is to determine if common factors, like credibility of the intervention and expectations to improve, can lead to symptom change. conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: Participants will be randomized to one of 8 different conditions (factorial trial), following the Multiphase optimization Strategy (MOST) primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants will be aware that they will be assigned to an intervention designed to help them with depressive symptoms. Participants will be aware that there are other arms of the study to which other participants are randomized, but they will not be aware of what these other arms entail. Additionally, the measures will be self-administered, so there is no scope for evaluator bias. whoMasked: PARTICIPANT count: 880 type: ESTIMATED name: Psychoeducation name: Testimonials and Saying is believing exercises name: Action planning name: Breathing exercise measure: Patient Health Questionnaire-8 measure: Patient Health Questionnaire-8 measure: Beck Hopelessness Scale-4 measure: Balanced measure of Psychological Needs scale measure: Credibility/Expectancy questionnaire measure: Intervention satisfaction star rating at post-intervention sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06322836 id: Protocol ID ABR number 83536 briefTitle: A Feasibility Study for Elective Cardioversion of Atrial Fibrillation at Home acronym: Electra-1 overallStatus: ENROLLING_BY_INVITATION date: 2024-02-07 date: 2024-06-01 date: 2024-06-01 date: 2024-03-21 date: 2024-03-21 name: RAV Brabant MWN class: OTHER name: Jeroen Bosch Ziekenhuis briefSummary: The goal of this pilot, non-controlled, non-randomised, single centre, prospective intervention feasibility study is to assess the feasibility of a home DC-ECV in the treatment of recurrent symptomatic AF performed by APP in 25 patients.
A composite of major adverse cardiovascular and cerebrovascular events (MACCE) occurring within 24 hours MACCE occurring during 6 weeks follow-up; any hospitalisation and all-cause mortality during 6 weeks follow-up; number (%) of patients in sinus rhythm at 1 hour in the post-shock observation period; idem at the end of 6 weeks follow-up; inventory of all interventions in the study related to cost-of-care. conditions: Emergency Medical Services conditions: Electric Countershock studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: a pilot, non-controlled, non-randomised, single centre study. The Electra-1 pilot study is a prospective intervention feasibility study. primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Duble current electro cardioversion measure: completion of cardioversion to sinus rhythm measure: Incidence of treatment-emergent adverse events (Safety endpoint a) measure: Incidence of treatment-emergent adverse events (Safety endpoint b) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RAV Brabant MWN city: 's-Hertogenbosch state: Noord Brabant zip: 5212VM country: Netherlands lat: 51.69917 lon: 5.30417 hasResults: False
nctId: NCT06322823 id: 2010.432 briefTitle: Direct Thawing of Vitrified Human Blastocyst overallStatus: COMPLETED date: 2020-01-01 date: 2022-12-31 date: 2023-12-31 date: 2024-03-21 date: 2024-03-21 name: Chinese University of Hong Kong class: OTHER briefSummary: There are more than million frozen embryo transfers around the world each year; a faster, safer, and cheaper method can save a significant amount of money for patients undergoing IVF treatment worldwide. conditions: IVF studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 116 type: ACTUAL name: direct thawing name: Vitrification measure: blastocysts survival rate measure: ferilization rate measure: pregnancy rate measure: live birth rate sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: David Yiu Leung Chan city: Hong Kong zip: 000000 country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06322810 id: ESP vs. PIFB briefTitle: ESP Versus PIFB for Analgesia in Open Cardiac Surgery: a Randomized Control Trial overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2026-04-01 date: 2024-03-21 date: 2024-03-21 name: Taichung Veterans General Hospital class: OTHER briefSummary: This clinical trial compares analgesia efficiency and recovery outcomes between two different fascial plane block techniques (ESPB vs.PIFB) in cardiac surgery patients participant population/health conditions\].
* Do patients who receive ESPB have better recovery outcomes conditions: Analgesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Erector spinae plane block (ESPB) name: Pecto-intercostal fascial plane blok (PIFB) measure: 48hr opioid consumption measure: Postoperative static pain scores-Day 1 measure: Postoperative static pain scores-Day 2 measure: Postoperative dynamic pain scores-Day 1 measure: Postoperative dynamic pain scores-Day 2 measure: postoperative incentive spirometry volume (ml)-Day 1 measure: postoperative incentive spirometry volume (ml)-Day 2 measure: postoperative incentive spirometry volume (ml)-Day 3 measure: QoL15 (pre-op) measure: QoL15 (POD3) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taichung Veterans General Hospital city: Taichung zip: 407 country: Taiwan name: Yi-Ting Chang, MD role: CONTACT phone: (+886)4-23592525 phoneExt: 4101 email: taco@vghtc.gov.tw name: Yi-Ting Chang, MD role: PRINCIPAL_INVESTIGATOR lat: 24.1469 lon: 120.6839 hasResults: False
nctId: NCT06322797 id: rTMSinStroke briefTitle: The Safety&Efficacy of Repetitive Transcranial Magnetic Stimulation for Post-Stroke Upper Extremity Function Improvement overallStatus: RECRUITING date: 2022-07-19 date: 2024-12-31 date: 2024-12-31 date: 2024-03-21 date: 2024-03-21 name: MinYoung Kim, MD, PhD class: OTHER briefSummary: A randomized, controlled, subject and rater-blind, exploratory clinical trial to evaluate the safety and efficacy of repetitive transcranial magnetic stimulation for improvement of upper extremity function after stroke. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 15 type: ESTIMATED name: rTMS name: rTMS name: Sham measure: Change of Fugl-Meyer Assessment measure: Change of Range of motion measure: Change of Berg Balance Scale measure: Change of Motor Assessment Scale measure: Change of Trunk Imbalance Scale measure: Change of Functional Ambulation Category measure: Change of Time up and go measure: Change of Manual muscle Test measure: Change of Action reach arm test measure: Change of Jebsen taylor hand function test measure: Change of Functional Independence Measure measure: Change of Modified Barthel index measure: Change of National Institutes of Health Stroke Scale measure: Change of Korean Mini Mental State Exam measure: Change of Clinical Dementia Rating measure: Change of Global Deterioration Scale measure: Change of Geriatric Depression Scale measure: Change of Brain imaging measure: Change of Electroencephalography measure: Change of Evoked Potential measure: Changes in test results of WBC(/uL), RBC(/uL), , Hct(%), PLT(/uL), Hgb(g/dL) measure: Changes in test results of CRP (mg/dL), glucose (mg/dL), BUN (mg/dL), creatinine (mg/dL), total cholesterol (mg/dL) measure: Changes in test results of AST(IU/L), ALT(IU/L) measure: Change of Motricity index sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Rehabilitation Medicine, CHA Bundang Medical Center status: RECRUITING city: Seongnam zip: 13496 country: Korea, Republic of name: MinYoung Kim, MD,PhD role: CONTACT phone: 82-31-780-2954 phoneExt: 2954 email: parkmijin@chamc.co.kr lat: 37.43861 lon: 127.13778 hasResults: False
nctId: NCT06322784 id: LiJingjing briefTitle: DF(Oat Bran) Intervention on Inflammation, Intestinal Flora, Disease Activity and Quality of Life in Patients With RA overallStatus: COMPLETED date: 2022-11-01 date: 2022-12-01 date: 2024-02-10 date: 2024-03-21 date: 2024-03-21 name: Shenzhen People's Hospital class: OTHER briefSummary: The goal of this clinical trial is to test in Rheumatoid arthritis. The main question it aims to answer are:
The experimental group was supplemented with dietary fiber for 12 weeks, and the control group was fed with the Mediterranean diet. Before and after the intervention, 1 tube of 3ml blood and 1 soybean-sized stool were taken and a questionnaire was made conditions: Rheumatoid Arthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Experimental group=1,Control Group=2, primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Researchers set blinding to reduce implementation bias whoMasked: INVESTIGATOR count: 25 type: ACTUAL name: Oat bran (dietary fiber) measure: Disease activity score measure: Quality of life score measure: Compliance of oat bran measure: Inflammatory indicators :TNF- α measure: Inflammatory indicators:IL-6 measure: Inflammatory indicators :IL-10 measure: Inflammatory indicators: ESR measure: Inflammatory indicators :CRP measure: gut flora measure: Adjustment of anti rheumatic drugs sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jingjing Li city: Shenzhen state: Guangdong zip: 518000 country: China lat: 22.54554 lon: 114.0683 hasResults: False
nctId: NCT06322771 id: APHP240376 briefTitle: Women's Refusal to Participate in a Randomized Trial Involving First-trimester Screening for Pre-eclampsia: Factors Associated With Refusal and Reasons for Acceptance and Refusal acronym: RANSPRE-refus overallStatus: RECRUITING date: 2024-04-11 date: 2025-03 date: 2025-03 date: 2024-03-21 date: 2024-04-15 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: The main objective is to assess whether there are factors associated with women's refusal to participate in a randomized clinical trial involving first-trimester screening for pre-eclampsia. The secondary objective is to qualitatively evaluate the reasons for acceptance and refusal to participate. conditions: Pregnancy Related studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 830 type: ESTIMATED name: Questionnaire name: Questionnaire measure: Factors associated with women's refusal measure: Number of acceptations measure: Number of refusals measure: Demographic characteristics measure: Questionnaire "acceptance" measure: Questionnaire "refusal" sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Port-Royal Maternity status: RECRUITING city: Paris state: IDF zip: 75014 country: France name: Yoann Athiel, MD role: CONTACT lat: 48.85341 lon: 2.3488 hasResults: False